Dompe 
Welcome,         Profile    Billing    Logout  
 5 Products   6 Diseases  5 Products   10 Trials   559 News 
28 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
reparixin (DF 1681Y) / Dompe
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
3
409
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
09/24
2013-002244-86: extention up to 3 years of the follow-up of patients treated with reparixin under protocol REP0110. estensione a 3 anni del follow-up dei pazienti trattati con Reparixin nello studio REP0110

Ongoing
2
3
Europe
Reparixin, DF 1681Y,
Dompé s.p.a., Dompé s.p.a.
patients who have received pancreatic islet transplantation pazienti che hanno ricevuto trapianto di isole pancreatiche
 
 
2021-000382-32: A study efficacy and safety of reparixin tablets in cancer related fatigue for breast cancer patients undergoing chemotherapy

Not yet recruiting
2
76
Europe
Reparixin, [Reparixin], Tablet
Dompé farmaceutici s.p.a., DOMPé FARMACEUTICI S.P.A., Dompé farmaceutici s.p.a., Dompé farmaceutici S.p.A.
Cancer related fatigue in patients with locally advanced or metastatic breast cancer, Cancer related fatigue in patients with breast cancer, Diseases [C] - Cancer [C04]
 
 
2022-001612-25: Phase 2, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as additional therapy in adult patients with Acute Respiratory Distress Syndrome Studio di fase II, multicentrico, randomizzato, in doppio cieco e controllato con placebo volto a valutare l'efficacia e la sicurezza di reparixin come terapia aggiuntiva in pazienti adulti con sindrome da distress respiratorio acuto

Not yet recruiting
2
66
Europe
Reparixin, [DF 1681Y], Tablet
DOMPé FARMACEUTICI S.P.A., Dompè farmaceutici s.p.a.
Acute Respiratory Distress Syndrome Sindrome da distress respiratorio acuto, Serious lung condition that causes low blood oxygen Grave condizione polmonare che causa un basso livello di ossigeno nel sangue, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05496868 / 2022-001612-25: Add-on Reparixin in Adult Patients With ARDS

Completed
2
66
Europe, US
Reparixin 600mg, REP, Matching Placebo, Control
Dompé Farmaceutici S.p.A, Dompè farmaceutici s.p.a.
Acute Respiratory Distress Syndrome, Adult
03/25
04/25
NCT05835466: Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Recruiting
2
26
US
reparixin
Icahn School of Medicine at Mount Sinai, Dompé Farmaceutici S.p.A
Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
12/25
12/27
Sentinel (cenegermin-bkbj) / Dompe
NCT06947850: DOMPE -MT Neurotrophic Keratitis

Active, not recruiting
4
10
US
Cenegermin Ophthalmic Solution [Oxervate]
Toyos Clinic
Dry Eye, Neurotrophic Keratitis
09/25
09/25
ChiCTR2200058806: Clinical study of Oxervate on the individualized treatment effect in patients with diabetic keratopathy

Not yet recruiting
4
24
 
Oxervate eyedrops
Qingdao Eye Hospital of Shandong First Medical University; Qingdao Eye Hospital of Shandong First Medical University, Dompé Pharmaceutical (Shanghai) Co., Ltd
Diabetic keratopathy
 
 
ChiCTR2100044759: A pilot study on the role of topical Cenegermin in enhancing regeneration of corneal nerves after small incision lenticule extraction (SMILE)

Recruiting
4
6
 
Senecimin drops ;placebo (normal saline)
the Eye and ENT Hospital of Fudan University; The Eye and ENT Hospital of Fudan University, self-raised
post refractive surgury
 
 
IMAGO, NCT06411145: Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis

Withdrawn
4
17
NA
OXERVATE® 0.002%, cenegermin-bkbj
Dompé Farmaceutici S.p.A
Neurotrophic Keratitis, Neurotrophic Keratopathy, Corneal Ulcer
11/24
11/24
2021-003749-39: A 4 week, Phase III, multicenter, double-masked, study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A. Studio di 4 settimane, di Fase III, multicentrico, in doppio cieco, per valutare la sicurezza e l'efficacia della soluzione oftalmica di Oxervate® (cenegermin) 20 mcg/mL in pazienti affetti da sindrome dell'occhio secco di Sjögren grave in trattamento con Ciclosporina A

Not yet recruiting
3
48
Europe
OXERVATE, [Recombinant Human Nerve Growth Factor (rhNGF)], Eye drops, Oxervate
DOMPé FARMACEUTICI S.P.A., Dompé farmaceutici S.p.A.
Severe Sjogren’s dry eye disease Sindrome dell'occhio secco di Sjögren grave, Severe Sjogren’s dry eye disease Sindrome dell'occhio secco di Sjögren grave, Diseases [C] - Eye Diseases [C11]
 
 
2021-003346-21: A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogren’s dry eye disease. Studio di fase III, multicentrico, di 4 settimane, a doppio mascheramento, controllato con veicolo, volto a valutare la sicurezza e l'efficacia di Oxervate® (cenegermin) 20 mcg/ml soluzione oftalmica rispetto al veicolo, in pazienti affetti da sindrome dell'occhio secco di Sjögren grave.

Not yet recruiting
3
100
Europe
OXERVATE, [Recombinant Human Nerve Growth Factor (rhNGF)], Eye drops, Oxervate
DOMPé FARMACEUTICI S.P.A., Dompé farmaceutici S.p.A.
Severe Sjogren’s dry eye disease Sindrome dell'occhio secco di Sjögren grave, Severe Sjogren’s dry eye disease Sindrome dell'occhio secco di Sjögren grave, Diseases [C] - Eye Diseases [C11]
 
 
NGF0121, NCT05133180 / 2021-003346-21: Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)

Completed
3
104
Europe, US
Oxervate, Cenegermin, Vehicle, Reference product
Dompé Farmaceutici S.p.A, Dompé farmaceutici S.p.A.
Dry Eye
09/22
12/22
NGF0221 - PROTEGO-2, NCT05136170 / 2021-003749-39: Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

Completed
3
85
Europe, US
Cenegermin, Oxervate®, Vehicle, Placebo
Dompé Farmaceutici S.p.A, Dompé farmaceutici S.p.A.
Dry Eye Disease
05/23
05/23
2019-002282-35: Nerve growth factor in pediatric severe traumatic brain injury : translational and clinical studies on a candidate biomarker and therapeutic drug Fattore di crescita neuronale nel trauma cranico grave pediatrico: studi traslazionali e clinici su un candidato biomarker e farmacologico

Ongoing
2
5
Europe
oxervate, [rh-NGF], Eye drops, solution, OXERVATE
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Ministero della Salute Ricerca Finalizzata
Persistent unresponsive wakefulness syndrome (UWS) Danni neurologici gravi secondari a trauma cranico (UWS), Persistent unresponsive wakefulness syndrome (UWS) Danni neurologici gravi secondari a trauma cranico (UWS), Diseases [C] - Nervous System Diseases [C10]
 
 
REDUCO, NCT06244316: A Study to Evaluate Safety and Efficacy of a New Formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution in Patients With Dry Eye Disease

Completed
2
317
Europe, US
rhNGF concentration 1, rhNGF concentration 2, Vehicle (Placebo solution)
Dompé Farmaceutici S.p.A
Dry Eye Disease
12/24
12/24
NCT04573647: OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate

Recruiting
N/A
10
US
Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]
Sight Medical Doctors PLLC, Dompé, US, Inc.
Neurotrophic Ulcer, Neurotrophic Keratitis, Neurotrophic Corneal Ulcer, Neurotrophic Keratoconjunctivitis
06/24
12/24
NCT04627571: Corneal Nerves After Treatment With Cenegermin

Completed
N/A
8
US
Cenegermin Ophthalmic Solution [Oxervate]
University of California, Los Angeles, Dompé Farmaceutici S.p.A
Neurotrophic Keratitis
03/25
03/25
DEFENDO, NCT05552261: Long Term Follow-up Study in Stage 1 NK Patients

Completed
N/A
24
US
Cenegemin in the DEFENDO Study, OXERVATE™
Dompé Farmaceutici S.p.A
Neurotrophic Keratitis
04/24
04/24
Aerosurf (lucinactant) / Windtree Therap, Dompe, Esteve, Lee's Pharm
2018-000106-32: An international study at different sites testing the safety and effectiveness of an investigational drug called lucinactant, which is to be inhaled to treat breathing problems in babies born prematurely at a gestational age of 26 to 32 weeks.

Not yet recruiting
2
130
Europe
Lyophilized lucinactant, R07AA-30, Nebuliser suspension
Windtree Therapeutics, Inc., Windtree Therapeutics, Inc.
Respiratory Distress Syndrome (RDS), Breathing difficulty in babies born prematurely, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ladarixin (DF-2156A) / Dompe
2020-001926-71: Study to evaluate the efficacy and the safety of ladaraxin in adult and adolescent patients with recent onset type 1 diabetes

Not yet recruiting
3
327
Europe
Ladarixin, DF 2156A, Capsule, hard
Dompe farmaceutici s.p.a., DOMPé FARMACEUTICI S.P.A., Dompe farmaceutici s.p.a.
Recent onset Type 1 Diabetes, Type 1 Diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2020-003296-18: Effect of the experimental drug ladarixin administered orally at a dose of 400 mg twice a day on insulin sensitivity. A phase 2, randomized, double-blind, placebo-controlled explorative study in obese patients with pre-diabetes eligible to bariatric surgery. Effetto del farmaco sperimentale ladarixin somministrato per via orale alla dose di 400mg due volte al giorno sulla sensibilità all’insulina. Studio di fase 2, esplorativo, randomizzato, in doppio cieco, controllato verso placebo, in pazienti obesi con pre-diabete candidati alla chirurgia bariatrica.

Ongoing
2
32
Europe
Ladarixin, [Ladarixin], Capsule, hard
DOMPé FARMACEUTICI S.P.A., Dompè farmaceutici spa
Obesity and pre-diabetes Obesità e pre-diabete, A medical condition characterized by excessive accumulation of body fat and blood glucose level above the normal value, but not yet in the diabetic range Condizione medica caratterizzata da un eccessivo accumulo di grasso corporeo e livelli di glucosio nel sangue superiori alla norma, ma non ancora nel range del diabete, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2022-000743-68: A Clinical Study to evaluate Ladarixin as an additional therapy to improve glycemic control in overweight insulin resistance patients with type 1 diabetes. Studio clinico con ladarixin come terapia aggiuntiva per migliorare il controllo glicemico in pazienti con diabete di tipo 1, sovrappeso ed insulino-resistenti

Not yet recruiting
2
86
Europe
Ladarixin, [DF2156A], Capsule, hard
DOMPé FARMACEUTICI S.P.A., Dompé farmaceutici S.P.A.
overweight insulin-resistant patients with type 1 diabetes Pazienti con diabete tipo 1, sovrappeso ed insulino-resistenti, Type 1 diabetes diabete di tipo 1, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
CONSERVA, NCT05368402 / 2022-000743-68: Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.

Terminated
2
3
Europe
Ladarixin, LDX, Placebo
Dompé Farmaceutici S.p.A, Dompé farmaceutici S.P.A.
Type 1 Diabetes
09/23
09/23
NCT04899271 / 2020-002966-15: A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

Terminated
2
25
Europe, US, RoW
Ladarixin, LDX, Placebo
Dompé Farmaceutici S.p.A
New-onset Type 1 Diabetes
04/23
10/23
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Active, not recruiting
2
140
Europe, US, RoW
Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo
Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.
Recent Onset type1 Diabetes
04/24
04/26
NCT05815186: Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Withdrawn
2
28
US
Sotorasib, Ladarixin
NYU Langone Health
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
04/25
04/26
NCT05815173: Ladarixin With Sotorasib in Advanced NSCLC

Recruiting
1
40
US
Sotorasib, Ladarixin
NYU Langone Health
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
08/25
08/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
reparixin (DF 1681Y) / Dompe
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
3
409
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
09/24
2013-002244-86: extention up to 3 years of the follow-up of patients treated with reparixin under protocol REP0110. estensione a 3 anni del follow-up dei pazienti trattati con Reparixin nello studio REP0110

Ongoing
2
3
Europe
Reparixin, DF 1681Y,
Dompé s.p.a., Dompé s.p.a.
patients who have received pancreatic islet transplantation pazienti che hanno ricevuto trapianto di isole pancreatiche
 
 
2021-000382-32: A study efficacy and safety of reparixin tablets in cancer related fatigue for breast cancer patients undergoing chemotherapy

Not yet recruiting
2
76
Europe
Reparixin, [Reparixin], Tablet
Dompé farmaceutici s.p.a., DOMPé FARMACEUTICI S.P.A., Dompé farmaceutici s.p.a., Dompé farmaceutici S.p.A.
Cancer related fatigue in patients with locally advanced or metastatic breast cancer, Cancer related fatigue in patients with breast cancer, Diseases [C] - Cancer [C04]
 
 
2022-001612-25: Phase 2, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as additional therapy in adult patients with Acute Respiratory Distress Syndrome Studio di fase II, multicentrico, randomizzato, in doppio cieco e controllato con placebo volto a valutare l'efficacia e la sicurezza di reparixin come terapia aggiuntiva in pazienti adulti con sindrome da distress respiratorio acuto

Not yet recruiting
2
66
Europe
Reparixin, [DF 1681Y], Tablet
DOMPé FARMACEUTICI S.P.A., Dompè farmaceutici s.p.a.
Acute Respiratory Distress Syndrome Sindrome da distress respiratorio acuto, Serious lung condition that causes low blood oxygen Grave condizione polmonare che causa un basso livello di ossigeno nel sangue, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05496868 / 2022-001612-25: Add-on Reparixin in Adult Patients With ARDS

Completed
2
66
Europe, US
Reparixin 600mg, REP, Matching Placebo, Control
Dompé Farmaceutici S.p.A, Dompè farmaceutici s.p.a.
Acute Respiratory Distress Syndrome, Adult
03/25
04/25
NCT05835466: Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Recruiting
2
26
US
reparixin
Icahn School of Medicine at Mount Sinai, Dompé Farmaceutici S.p.A
Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
12/25
12/27
Sentinel (cenegermin-bkbj) / Dompe
NCT06947850: DOMPE -MT Neurotrophic Keratitis

Active, not recruiting
4
10
US
Cenegermin Ophthalmic Solution [Oxervate]
Toyos Clinic
Dry Eye, Neurotrophic Keratitis
09/25
09/25
ChiCTR2200058806: Clinical study of Oxervate on the individualized treatment effect in patients with diabetic keratopathy

Not yet recruiting
4
24
 
Oxervate eyedrops
Qingdao Eye Hospital of Shandong First Medical University; Qingdao Eye Hospital of Shandong First Medical University, Dompé Pharmaceutical (Shanghai) Co., Ltd
Diabetic keratopathy
 
 
ChiCTR2100044759: A pilot study on the role of topical Cenegermin in enhancing regeneration of corneal nerves after small incision lenticule extraction (SMILE)

Recruiting
4
6
 
Senecimin drops ;placebo (normal saline)
the Eye and ENT Hospital of Fudan University; The Eye and ENT Hospital of Fudan University, self-raised
post refractive surgury
 
 
IMAGO, NCT06411145: Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis

Withdrawn
4
17
NA
OXERVATE® 0.002%, cenegermin-bkbj
Dompé Farmaceutici S.p.A
Neurotrophic Keratitis, Neurotrophic Keratopathy, Corneal Ulcer
11/24
11/24
2021-003749-39: A 4 week, Phase III, multicenter, double-masked, study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A. Studio di 4 settimane, di Fase III, multicentrico, in doppio cieco, per valutare la sicurezza e l'efficacia della soluzione oftalmica di Oxervate® (cenegermin) 20 mcg/mL in pazienti affetti da sindrome dell'occhio secco di Sjögren grave in trattamento con Ciclosporina A

Not yet recruiting
3
48
Europe
OXERVATE, [Recombinant Human Nerve Growth Factor (rhNGF)], Eye drops, Oxervate
DOMPé FARMACEUTICI S.P.A., Dompé farmaceutici S.p.A.
Severe Sjogren’s dry eye disease Sindrome dell'occhio secco di Sjögren grave, Severe Sjogren’s dry eye disease Sindrome dell'occhio secco di Sjögren grave, Diseases [C] - Eye Diseases [C11]
 
 
2021-003346-21: A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogren’s dry eye disease. Studio di fase III, multicentrico, di 4 settimane, a doppio mascheramento, controllato con veicolo, volto a valutare la sicurezza e l'efficacia di Oxervate® (cenegermin) 20 mcg/ml soluzione oftalmica rispetto al veicolo, in pazienti affetti da sindrome dell'occhio secco di Sjögren grave.

Not yet recruiting
3
100
Europe
OXERVATE, [Recombinant Human Nerve Growth Factor (rhNGF)], Eye drops, Oxervate
DOMPé FARMACEUTICI S.P.A., Dompé farmaceutici S.p.A.
Severe Sjogren’s dry eye disease Sindrome dell'occhio secco di Sjögren grave, Severe Sjogren’s dry eye disease Sindrome dell'occhio secco di Sjögren grave, Diseases [C] - Eye Diseases [C11]
 
 
NGF0121, NCT05133180 / 2021-003346-21: Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)

Completed
3
104
Europe, US
Oxervate, Cenegermin, Vehicle, Reference product
Dompé Farmaceutici S.p.A, Dompé farmaceutici S.p.A.
Dry Eye
09/22
12/22
NGF0221 - PROTEGO-2, NCT05136170 / 2021-003749-39: Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

Completed
3
85
Europe, US
Cenegermin, Oxervate®, Vehicle, Placebo
Dompé Farmaceutici S.p.A, Dompé farmaceutici S.p.A.
Dry Eye Disease
05/23
05/23
2019-002282-35: Nerve growth factor in pediatric severe traumatic brain injury : translational and clinical studies on a candidate biomarker and therapeutic drug Fattore di crescita neuronale nel trauma cranico grave pediatrico: studi traslazionali e clinici su un candidato biomarker e farmacologico

Ongoing
2
5
Europe
oxervate, [rh-NGF], Eye drops, solution, OXERVATE
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Ministero della Salute Ricerca Finalizzata
Persistent unresponsive wakefulness syndrome (UWS) Danni neurologici gravi secondari a trauma cranico (UWS), Persistent unresponsive wakefulness syndrome (UWS) Danni neurologici gravi secondari a trauma cranico (UWS), Diseases [C] - Nervous System Diseases [C10]
 
 
REDUCO, NCT06244316: A Study to Evaluate Safety and Efficacy of a New Formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution in Patients With Dry Eye Disease

Completed
2
317
Europe, US
rhNGF concentration 1, rhNGF concentration 2, Vehicle (Placebo solution)
Dompé Farmaceutici S.p.A
Dry Eye Disease
12/24
12/24
NCT04573647: OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate

Recruiting
N/A
10
US
Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]
Sight Medical Doctors PLLC, Dompé, US, Inc.
Neurotrophic Ulcer, Neurotrophic Keratitis, Neurotrophic Corneal Ulcer, Neurotrophic Keratoconjunctivitis
06/24
12/24
NCT04627571: Corneal Nerves After Treatment With Cenegermin

Completed
N/A
8
US
Cenegermin Ophthalmic Solution [Oxervate]
University of California, Los Angeles, Dompé Farmaceutici S.p.A
Neurotrophic Keratitis
03/25
03/25
DEFENDO, NCT05552261: Long Term Follow-up Study in Stage 1 NK Patients

Completed
N/A
24
US
Cenegemin in the DEFENDO Study, OXERVATE™
Dompé Farmaceutici S.p.A
Neurotrophic Keratitis
04/24
04/24
Aerosurf (lucinactant) / Windtree Therap, Dompe, Esteve, Lee's Pharm
2018-000106-32: An international study at different sites testing the safety and effectiveness of an investigational drug called lucinactant, which is to be inhaled to treat breathing problems in babies born prematurely at a gestational age of 26 to 32 weeks.

Not yet recruiting
2
130
Europe
Lyophilized lucinactant, R07AA-30, Nebuliser suspension
Windtree Therapeutics, Inc., Windtree Therapeutics, Inc.
Respiratory Distress Syndrome (RDS), Breathing difficulty in babies born prematurely, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ladarixin (DF-2156A) / Dompe
2020-001926-71: Study to evaluate the efficacy and the safety of ladaraxin in adult and adolescent patients with recent onset type 1 diabetes

Not yet recruiting
3
327
Europe
Ladarixin, DF 2156A, Capsule, hard
Dompe farmaceutici s.p.a., DOMPé FARMACEUTICI S.P.A., Dompe farmaceutici s.p.a.
Recent onset Type 1 Diabetes, Type 1 Diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2020-003296-18: Effect of the experimental drug ladarixin administered orally at a dose of 400 mg twice a day on insulin sensitivity. A phase 2, randomized, double-blind, placebo-controlled explorative study in obese patients with pre-diabetes eligible to bariatric surgery. Effetto del farmaco sperimentale ladarixin somministrato per via orale alla dose di 400mg due volte al giorno sulla sensibilità all’insulina. Studio di fase 2, esplorativo, randomizzato, in doppio cieco, controllato verso placebo, in pazienti obesi con pre-diabete candidati alla chirurgia bariatrica.

Ongoing
2
32
Europe
Ladarixin, [Ladarixin], Capsule, hard
DOMPé FARMACEUTICI S.P.A., Dompè farmaceutici spa
Obesity and pre-diabetes Obesità e pre-diabete, A medical condition characterized by excessive accumulation of body fat and blood glucose level above the normal value, but not yet in the diabetic range Condizione medica caratterizzata da un eccessivo accumulo di grasso corporeo e livelli di glucosio nel sangue superiori alla norma, ma non ancora nel range del diabete, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2022-000743-68: A Clinical Study to evaluate Ladarixin as an additional therapy to improve glycemic control in overweight insulin resistance patients with type 1 diabetes. Studio clinico con ladarixin come terapia aggiuntiva per migliorare il controllo glicemico in pazienti con diabete di tipo 1, sovrappeso ed insulino-resistenti

Not yet recruiting
2
86
Europe
Ladarixin, [DF2156A], Capsule, hard
DOMPé FARMACEUTICI S.P.A., Dompé farmaceutici S.P.A.
overweight insulin-resistant patients with type 1 diabetes Pazienti con diabete tipo 1, sovrappeso ed insulino-resistenti, Type 1 diabetes diabete di tipo 1, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
CONSERVA, NCT05368402 / 2022-000743-68: Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.

Terminated
2
3
Europe
Ladarixin, LDX, Placebo
Dompé Farmaceutici S.p.A, Dompé farmaceutici S.P.A.
Type 1 Diabetes
09/23
09/23
NCT04899271 / 2020-002966-15: A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

Terminated
2
25
Europe, US, RoW
Ladarixin, LDX, Placebo
Dompé Farmaceutici S.p.A
New-onset Type 1 Diabetes
04/23
10/23
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Active, not recruiting
2
140
Europe, US, RoW
Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo
Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.
Recent Onset type1 Diabetes
04/24
04/26
NCT05815186: Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Withdrawn
2
28
US
Sotorasib, Ladarixin
NYU Langone Health
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
04/25
04/26
NCT05815173: Ladarixin With Sotorasib in Advanced NSCLC

Recruiting
1
40
US
Sotorasib, Ladarixin
NYU Langone Health
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
08/25
08/26

Download Options